Intra-Cellular Therapies, Inc.
NOVEL METHODS

Abstract:

The disclosure provides methods for the acute treatment of depression and/or anxiety, for the enhancement of mTOR (e.g., mTORC1) signaling, and for the reduction of neuroinflammation, comprising administering to a patient in need thereof, a therapeutically effective amount of a 5-HT.sub.2A/mu-opioid receptor or 5-HT.sub.2A/D1 and/or D2/mu-opioid receptor ligand.